Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Malignancy|Safety and Tolerability|Pharmacokinetics|Pharmacodynamics|Tumour Response|Advanced or Metastatic Breast Cancer|Ovarian Cancer|Cervical Cancer|Endometrial Cancer|PIK3CA|AKT1|PTEN|ER Positive|HER2 Positive
Interventions: DRUG: AZD5363|DRUG: AZD5363|DRUG: AZD5363|DRUG: AZD5363
Sponsor: AstraZeneca